Are you or your loved ones suffering from leukemia?

You may be eligible to participate in a leukemia clinical trial.

Are you or your loved ones suffering from leukemia? You may be eligible to participate in a leukemia clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Leukemia
NCT02392572 | Phase 1 phase 2 | Interventional
What you may receive

Study related treatment at no cost

Are you or your loved ones suffering from leukemia?

You may be eligible to participate in a leukemia clinical trial.

Are you or your loved ones suffering from leukemia? You may be eligible to participate in a leukemia clinical trial.

Recruiting

Male & Female

18 +

years old

The goal of Phase I of this clinical research study is to find the highest tolerable dose of ONC201 alone or in combination with low dose cytarabine (LDAC) that can be given to patients with relapsed or refractory AML, ALL, or MDS. The goal of Phase II of this study is to learn if the dose of ONC201 given alone or in combination with LDAC that is found in Phase I can help to control the disease. The safety of the study drug will be studied in both phases of this study. This is the first study using ONC201 in humans. ONC201 given alone or in combination with LDAC is in a very early stage of development for use in humans. Providing direct medical benefit to you is not the purpose of this study. While Phase II will look at the effectiveness of the study drug given alone or in combination with LDAC, the main purpose of this study is to learn about the safety of the drug.

Where you'll go

Selected location

University of Texas MD Anderson Cancer Center

University of Texas MD Anderson Cancer Center Change

1515 Holcombe Boulevard, Houston, TX, USA 77030

Get directions | Learn more

Interested in participating?

Selected location

University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard, Houston, TX, USA 77030


By clicking the button, you agree to the Terms and Privacy Policy.

Sign up now